|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: QSER1 |
Gene summary for QSER1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | QSER1 | Gene ID | 79832 |
| Gene name | glutamine and serine rich 1 | |
| Gene Alias | QSER1 | |
| Cytomap | 11p13 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | B3KWV1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79832 | QSER1 | P17T-E | Human | Esophagus | ESCC | 3.97e-03 | 1.71e-01 | 0.1278 |
| 79832 | QSER1 | P20T-E | Human | Esophagus | ESCC | 5.34e-14 | 2.24e-01 | 0.1124 |
| 79832 | QSER1 | P21T-E | Human | Esophagus | ESCC | 9.12e-15 | 2.49e-01 | 0.1617 |
| 79832 | QSER1 | P22T-E | Human | Esophagus | ESCC | 1.77e-14 | 3.43e-01 | 0.1236 |
| 79832 | QSER1 | P23T-E | Human | Esophagus | ESCC | 9.43e-08 | 6.37e-02 | 0.108 |
| 79832 | QSER1 | P24T-E | Human | Esophagus | ESCC | 1.32e-05 | 7.88e-02 | 0.1287 |
| 79832 | QSER1 | P26T-E | Human | Esophagus | ESCC | 6.90e-06 | 1.50e-01 | 0.1276 |
| 79832 | QSER1 | P27T-E | Human | Esophagus | ESCC | 3.95e-13 | 1.22e-01 | 0.1055 |
| 79832 | QSER1 | P28T-E | Human | Esophagus | ESCC | 1.01e-19 | 3.88e-01 | 0.1149 |
| 79832 | QSER1 | P30T-E | Human | Esophagus | ESCC | 6.52e-14 | 6.27e-01 | 0.137 |
| 79832 | QSER1 | P31T-E | Human | Esophagus | ESCC | 1.36e-13 | 2.29e-01 | 0.1251 |
| 79832 | QSER1 | P32T-E | Human | Esophagus | ESCC | 3.77e-14 | 3.07e-01 | 0.1666 |
| 79832 | QSER1 | P36T-E | Human | Esophagus | ESCC | 6.45e-07 | 1.73e-01 | 0.1187 |
| 79832 | QSER1 | P37T-E | Human | Esophagus | ESCC | 3.90e-12 | 3.61e-01 | 0.1371 |
| 79832 | QSER1 | P39T-E | Human | Esophagus | ESCC | 2.23e-10 | 1.50e-02 | 0.0894 |
| 79832 | QSER1 | P42T-E | Human | Esophagus | ESCC | 2.39e-11 | 2.28e-01 | 0.1175 |
| 79832 | QSER1 | P44T-E | Human | Esophagus | ESCC | 9.12e-04 | 3.56e-02 | 0.1096 |
| 79832 | QSER1 | P47T-E | Human | Esophagus | ESCC | 4.51e-15 | 1.02e-01 | 0.1067 |
| 79832 | QSER1 | P48T-E | Human | Esophagus | ESCC | 1.61e-15 | 2.03e-01 | 0.0959 |
| 79832 | QSER1 | P49T-E | Human | Esophagus | ESCC | 6.54e-03 | 5.44e-01 | 0.1768 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| QSER1 | SNV | Missense_Mutation | c.2913G>T | p.Glu971Asp | p.E971D | Q2KHR3 | protein_coding | tolerated_low_confidence(0.22) | benign(0.007) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| QSER1 | SNV | Missense_Mutation | c.2206N>G | p.Leu736Val | p.L736V | Q2KHR3 | protein_coding | deleterious(0.02) | benign(0.089) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| QSER1 | SNV | Missense_Mutation | c.2372N>G | p.Ser791Cys | p.S791C | Q2KHR3 | protein_coding | deleterious(0) | possibly_damaging(0.635) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| QSER1 | SNV | Missense_Mutation | c.2554N>T | p.Asp852Tyr | p.D852Y | Q2KHR3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| QSER1 | SNV | Missense_Mutation | c.2801C>T | p.Pro934Leu | p.P934L | Q2KHR3 | protein_coding | deleterious_low_confidence(0.03) | benign(0.018) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| QSER1 | SNV | Missense_Mutation | c.1339C>G | p.Gln447Glu | p.Q447E | Q2KHR3 | protein_coding | tolerated(0.07) | benign(0.315) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| QSER1 | SNV | Missense_Mutation | c.1460C>G | p.Ser487Cys | p.S487C | Q2KHR3 | protein_coding | deleterious(0) | possibly_damaging(0.554) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| QSER1 | SNV | Missense_Mutation | c.607G>A | p.Ala203Thr | p.A203T | Q2KHR3 | protein_coding | tolerated(0.11) | benign(0.162) | TCGA-AO-A0JG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| QSER1 | SNV | Missense_Mutation | novel | c.2083N>G | p.His695Asp | p.H695D | Q2KHR3 | protein_coding | deleterious(0.01) | benign(0.058) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| QSER1 | SNV | Missense_Mutation | rs776302648 | c.3144N>T | p.Met1048Ile | p.M1048I | Q2KHR3 | protein_coding | tolerated_low_confidence(0.22) | benign(0) | TCGA-AR-A1AS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |